Market revenue in 2023 | USD 113.5 million |
Market revenue in 2030 | USD 190.3 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.33% in 2023. Horizon Databook has segmented the France central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
The France central lab market is projected to grow at a lucrative rate during the forecast period, owing to high cancer prevalence and increasing burden of chronic diseases. According to Globocan 2020, around 467,965 new cases of cancer were diagnosed in France in 2020.
In the same year, France was involved in about 11%, or 319 trials, of 2,972 clinical trials conducted globally. The country ranked third in Europe in terms of the number of trials conducted, with oncology accounting for 45% of the trials conducted, while rare diseases formed a 20% share, immune system disorders trials were 9%, and advanced therapy medicinal products accounted for 8%.
Hence, clinical research activities pertaining to early diagnosis and evaluation of cancer treatment options are expected to raise the demand for central lab services in France. Several initiatives are being undertaken in France to enhance data transparency in clinical trials.
Horizon Databook provides a detailed overview of country-level data and insights on the France central lab market , including forecasts for subscribers. This country databook contains high-level insights into France central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account